Xinruibai is long-acting recombinant human granulocyte colony-stimulating factor, which is a kind of drug to raise the number of leukocytes in the peripheral blood. It can promote the proliferation, division and maturation of the progenitor cells of the granulocyte lineage in the bone marrow and release them into the peripheral blood, so as to raise the number of leukocytes in the peripheral blood, and also increase the phagocytosis of leukocytes in the peripheral blood. It is clinically used in patients with leukopenia caused by various reasons, especially in the treatment of granulocytopenia caused by radiotherapy and chemotherapy. The effective period of Xinruibai is 7-14 days, and it can continuously promote the proliferation of granulocytes in the bone marrow within half a month after one application, and it can be injected subcutaneously once 48 hours after the cessation of chemotherapy, so it is more convenient to apply, and it is widely used in clinics nowadays.